Please wait while we open this resource.
K
Clinical reviews
Anticoagulation for Atrial Fibrillation with Intermediate Stroke
Daehoon Kim, M.D.
PDF202612 pages184 KB
The study enrolled 1,803 participants with a CHA₂DS₂‑VASc score of 1 (men) or 2 (women) and randomly assigned them to DOAC therapy or no anticoagulation. The primary composite endpoint included stroke, systemic embolism, major bleeding, or cardiovascular death over 24 months. Results showed a lower incidence of the composite outcome in the DOAC group, while serious adverse events were comparable between groups. Baseline characteristics, safety data, and detailed adverse‑event tables are provided. The trial addresses the evidence gap highlighted by current U.S. and European guidelines for this risk category.
Sign in to open
Ask this resource
Answers use this document only.
Your first question is free.
More like this
Resources from the same specialty and type. Curated links will replace these when added.
Clinical Resources
Documents that extend or complement this resource.
SURVIVAL AFTER INITIAL STRESS TESTING VS ANATOMIC TESTING IN SUSPECTED CORONARY ARTERY DISEASE
Same clinical topic · Cardiology
PRACTICAL CARDIO-ONCOLOGY
Same clinical topic · Cardiology
OXFORD CARDIOLOGY LIBRARY: Hypertension
Same clinical topic · Cardiology
CARDIAC INVOLVEMENT IN PARASITIC INFECTIONS
Same clinical topic · Cardiology
The Athlete’s ECG
Same clinical topic · Cardiology
Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review
Same clinical topic · Cardiology
Current ECG Aspects of Interatrial Block
Same clinical topic · Cardiology
Arrhythmic mitral valve prolapse in 2023: Evidence-based update
Same clinical topic · Cardiology
INTERPRETING THE NORMAL PACEMAKER
Same clinical topic · Cardiology